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Pegylated human recombinant leptin (PEG-OB) causes additional
weight loss in severely energy-restricted, overweight men1–3
Chris J Hukshorn, Margriet S Westerterp-Plantenga, and Wim HM Saris
ABSTRACT
Background: Increasing evidence suggests that falling leptin con-
centrations observed during fasting act as a peripheral signal of
starvation, which serves to conserve energy in the face of limited
reserves. An extension of this hypothesis is that exogenous leptin
should affect energy regulation during severe energy restriction.
Objective: To explore this hypothesis, we assessed whether ele-
vated leptin concentrations achieved with the use of long-acting
pegylated human recombinant leptin [polyethylene glycol–OB
protein (PEG-OB)] affected weight loss and changes in body com-
position, energy expenditure, appetite, and metabolic variables
during semistarvation in healthy overweight men.
Design: A randomized, double-blind, placebo-controlled study
was executed in overweight men with a mean (± SEM) age of
34.8 ± 1.3 y and body mass index (in kg/m2) of 28.8 ± 0.5. All
subjects received weekly treatment with 80 mg PEG-OB (n = 12)
or matching placebo (n = 10) for 46 d while their energy intake
was reduced to 2.1 MJ/d by means of a very-low-energy diet.
Body composition (hydrodensitometry and deuterium dilution),
energy expenditure (ventilated hood), and appetite (visual ana-
logue scales) were evaluated at the start and the end of the study.
Metabolic variables were measured throughout the study period.
Results: Compared with placebo treatment, treatment with PEG-
OB led to significant (P < 0.03) additional weight loss (14.6 ± 0.8
compared with 11.8 ± 0.9 kg) and a reduction in appetite (P < 0.05)
after 46 d, but the 2 treatment groups did not differ significantly
in changes in body composition, energy expenditure, and meta-
bolic variables.
Conclusion: Our observations support the hypothesis that the
decrease in leptin concentrations during starvation increases
appetite in humans. Am J Clin Nutr 2003;77:771–6.
KEY WORDS Leptin, pegylated human recombinant leptin,
polyethylene glycol–OB protein, PEG-OB, semistarvation,
very-low-energy diet, body composition, energy expenditure,
appetite, weight loss, men
INTRODUCTION
Leptin, the 16-kDa protein hormone encoded by the ob gene,
is secreted primarily from adipose tissue and is involved in the
regulation of food intake and metabolism via hypothalamic
mechanisms (1–4). Other extrahypothalamic areas in which lep-
tin has been implicated are glucose homeostasis, hematopoiesis,
angiogenesis, and immune responses. Furthermore, leptin may
act as an important regulator of neuroendocrine and reproduc-
tive functions (5).
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Initially, leptin was considered to function as the predicted and
long-sought adipostatic hormone. According to this hypothesis, ris-
ing concentrations of leptin with increasing adiposity would gen-
erate a signal to reduce food intake and increase energy expenditure
to limit further weight gain. However, resistance to the proposed
antiobesity action of leptin is observed in both animals (6, 7) and
humans (8). In addition, even the supraphysiologic leptin concen-
trations obtained during several clinical trials to date failed to signi-
ficantly affect weight loss during mild hypoenergetic conditions
(9–11) or energy expenditure during weight maintenance (12).
The widespread occurrence of leptin resistance may reflect the
fact that the inability to store energy efficiently at times of abun-
dance is evolutionarily disadvantageous. According to this alter-
native view proposed on the basis of animal data, evolution would
favor a leptin dose-response curve that functions briskly as a
switch between the fed and fasted state but fails to limit further
energy storage as concentrations increase with increasing energy
stores (13, 14). An extension of this hypothesis is that exogenous
leptin should affect energy regulation when administrated during
severe energy restriction. To test this hypothesis, we executed a
randomized, double-blind, placebo-controlled study to investigate
whether elevated leptin concentrations achieved with the use of
long-acting pegylated human recombinant leptin [polyethylene
glycol–OB protein (PEG-OB)] affected weight loss and changes
in body composition, energy expenditure, appetite, and metabolic
variables during semistarvation induced by a very-low-energy diet
(VLED) in healthy, overweight men.
SUBJECTS AND METHODS
Subjects
Twenty-four healthy, overweight male volunteers were
recruited by local advertising, screened, and enrolled in the study
after they provided written informed consent. The study was
Original Research Communications
772 HUKSHORN ET AL
approved by the Medical Ethical Committee of Maastricht Uni-
versity. Overweight and mildly obese men who were 18–45 y of
age and had a body mass index (BMI; in kg/m2) between 25 and
32 were eligible for inclusion. Additional inclusion criteria were
detailed medical and psychiatric histories and a physical exami-
nation with negative findings, including no medical condition
present, no use of prescription medication, and no smoking. Each
participant had normal biochemical tests of renal, hepatic, meta-
bolic, and hematologic function and no electrocardiogram abnor-
malities. Subjects who had a history of drug abuse or alcoholism
or were currently using drugs or alcohol, had atopy or hypersen-
sitivity to pegylated proteins, or had experienced a weight loss of
> 3 kg in the previous 3 mo were excluded from the study.
Study design
This single-center trial had a prospective, randomized, double-
blind, placebo-controlled group design. After the screening, 24
subjects were selected and enrolled in the trial. The study was
divided into 3 phases: 1) baseline characterization (days 14,
8, and 1), 2) PEG-OB or placebo treatment and a VLED for 46 d
(days 1–46), and 3) follow-up for 2 wk (days 50 and 57). Base-
line measurements were performed before (days 14 and 8)
and at the start (day 1) of the diet and treatment period. The
measurements on day 1 consisted of measurements of energy
expenditure, body composition, and metabolic profile (includ-
ing oral glucose tolerance). Subjects were stratified and
matched into pairs according to age, BMI, and fasting serum
leptin and insulin concentrations to achieve balanced treatment
groups. Randomization numbers for subjects were generated
and incorporated into the double-blind labeling by an inde-
pendent third party.
At the start of the treatment period (day 1) all subjects were
prescribed a VLED to induce a state of semistarvation for the next
46 d. The VLED (Modifast; Novartis, Breda, Netherlands) was a
protein-enriched formula diet (containing 44%, 14%, and 42% of
energy as protein, fat, and carbohydrate, respectively) that pro-
vided 2.1 MJ/d. The dietary prescription was discussed every
week with a dietitian. Adherence to the diet was confirmed by
measurements of body weight loss. Treatment consisted of weekly
administration of either 80 mg PEG-OB [8 mL of a 10-mg/mL
solution; mean (± SEM) of 1.17 ± 0.02 mg/kg fat-free mass
(FFM); Hoffmann-La Roche Inc, Nutley, NJ] or matching placebo
(8 mL) that was given subcutaneously in the paraumbilical region
during the VLED period. The subjects returned to the laboratory
in a fasting state on days 8, 15, 22, 29, 36, and 43 to receive treat-
ment after their weight and vital signs (pulse, respiratory rate, and
blood pressure) were recorded. Blood samples were drawn for
safety laboratory tests and measurements of metabolites on days
1, 8, 15, 25, and 46. At the end of the 46-d treatment period, meas-
urements of energy expenditure, body composition, and metabolic
profile were repeated. During the next 2 wk, the subjects received
less formula diet and were instructed to supplement this with a
free choice of habitual food items. Vital signs and body weight
during this follow-up period were measured on days 50 and 57.
Safety was monitored by documentation of adverse events and
recording of vital signs at each visit. In addition, urine analyses,
routine serum chemistry measurements, and blood cell counts
were conducted regularly throughout the study. Standard clinical
chemistry measurements and blood cell counts were conducted at
the certified central laboratory of the University Hospital Maas-
tricht, Netherlands.
Polyethylene glycol–OB protein
Recombinant methionyl human leptin has a reported average
terminal half-life of 4 h in humans, and daily administration
is required to obtain sustained blood concentrations (9). Modifi-
cation of proteins through covalent linkage of polyethylene gly-
col polymers to the proteins results in reduced immunogenicity
and increased serum half-life for many proteins (15). Recombi-
nant native human leptin, expressed and purified from Escherichia
coli, was chemically conjugated to a species of branched PEGs
with an average molecular mass of 42 kDa in a 1:1 ratio. The
result was a globular PEG–native human leptin polymer (PEG-OB)
with increased molecular size. PEG-OB at a concentration of
10 mg/mL was placed in sterile glass vials containing 1.3 mL.
Preclinical studies with PEG-OB indicate an extended half-life
(> 48 h) and efficacy for reduction of food intake and body
weight in animals (16). Our previous study in obese male sub-
jects clearly showed sustained elevated blood concentrations
after weekly subcutaneous dosing of PEG-OB in humans. Mean
peak serum PEG-OB concentrations were achieved 72 h after
dosing, followed by a return to the elevated predose concentra-
tions after 1 wk (10).
Body composition, energy expenditure, and appetite profile
Body weight was measured on a calibrated digital scale accu-
rate to 0.1 kg, and height was measured to the nearest 0.01 m.
Body composition was determined after the ventilated-hood
measurements obtained in the morning by using the combination
of hydrodensitometry and deuterium dilution according to the
Maastricht protocol (17). Body composition was calculated
according to the equations of Siri (18). Energy expenditure and
substrate utilization were measured with the use of a ventilated
hood after the subjects fasted overnight. After the subjects had
been supine for 15 min, their oxygen consumption and carbon
dioxide production were measured for 45 min by means of a
computerized, open-circuit ventilated-hood system. The resting
metabolic rate and the respiratory quotient were calculated
according to the method of de Weir (19) over the 15-min inter-
val with the lowest SD.
The subjects’ appetite profile was measured while they were in
a fasted state before breakfast and included determination of the
degree of dietary restraint. The appetite profile was determined by
averaging the ratings of actual appetite, hunger, and desire to eat
on 100-mm anchored visual analogue scales (20). The appetite
profile before breakfast was completed on days 1 and 46.
Measurements of metabolic profile and pharmacokinetics
Venous blood was sampled on days 1, 8, 15, 25, and 46 after
the subjects had fasted overnight. Plasma or serum was extracted
by centrifugation for 10 min at 1000  g and 4 C, frozen in liq-
uid nitrogen, and stored at 80 C until further analysis. Plasma
substrate concentrations were determined enzymatically in dupli-
cate by using the hexokinase method (Roche, Basel, Switzerland)
for glucose, the Wako NEFA C kit (Wako Chemicals, Neuss, Ger-
many) for free fatty acids, the glycerol kinase method (Boehringer
Mannheim GmbH, Mannheim, Germany) for free glycerol, the
lipase method (Sigma Diagnostics, St Louis) for triacylglycerol,
the CHOD-PAP method (Boehringer Mannheim GmbH) for cho-
lesterol, and the -hydroxybutyrate dehydrogenase method
(Sigma Diagnostics, St Louis) for -hydroxybutyrate. To avoid
interassay variability, all specimens for a given substance were
run in a single assay.
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TABLE 1
Baseline characteristics of the 2 matched groups1
Characteristic Placebo (n = 12) PEG-OB (n = 12)
Age (y) 34.9 ± 1.3 (24.0–40.0) 34.6 ± 1.2 (26.0–41.0)
Weight (kg) 95.0 ± 3.2 (77.2–113.9) 97.1 ± 1.8 (87.5–106.6)
BMI (kg/m2) 28.6 ± 0.5 (25.2–31.2) 28.9 ± 0.4 (27.3–31.2)
Leptin (ng/mL) 7.3 ± 0.9 (4.3–16.3) 7.0 ± 0.8 (2.3–12.9)
Insulin (mU/L) 9.7 ± 1.8 (4.0–26.0) 7.8 ± 1.3 (1.9–17.0)
1 x– ± SEM; range in parentheses. PEG-OB, pegylated human recombi-
nant leptin (polyethylene glycol–OB protein). There were no significant
differences between the groups.
FIGURE 1. Effect of 80 mg pegylated human recombinant leptin
[polyethylene glycol–OB protein (PEG-OB)] (; n = 12) or matching
placebo (; n = 10) administered weekly and of severe energy restriction
(2.1 MJ/d) on mean (± SEM) weight loss from the start of the treatment
(day 1), through the diet period (day 46), to the end of the 2-wk follow-up
period (day 57). *Significantly different from the PEG-OB group, P < 0.05
(interaction of time and treatment; two-factor repeated-measures ANOVA
with Scheffe’s F procedure).
Serum insulin concentrations were measured at the certified
central laboratory of the University Hospital Maastricht,
Netherlands. Total leptin concentrations (endogenous leptin
plus PEG-OB) were measured according to the method described
previously (10).
Insulin resistance throughout the study was estimated by using
the HOMA-R method with fasting plasma glucose and serum
insulin concentrations (21). For determining oral glucose toler-
ance, a standard 2-h oral-glucose-tolerance test was performed on
days 1 and 46 after the subjects had fasted overnight. In short, an
intravenous cannula was placed in an antecubital vein. After a
baseline blood sample was drawn, the subjects ingested 75 g glu-
cose dissolved in 250 mL water. Next, blood samples were
obtained 30, 60, and 120 min after the consumption of the solution
for measurements of plasma glucose concentration.
Statistics
Changes from baseline to the end of the study were compared
between the PEG-OB and placebo groups with two-factor repeated-
measures analysis of variance with a group  time interaction.
When significant differences were found, a post hoc Scheffe’s pro-
cedure was used to determine the location of the difference. All sta-
tistics were executed with STATVIEW (version 5.0; SAS Institute
Inc, Cary, NC). All statistical tests were two-sided, and significance
was defined as P < 0.05. All data are presented as means ± SEMs.
RESULTS
The characteristics of the subjects before the intervention are pre-
sented in Table 1. The variables used to match subjects into pairs
were not significantly different, and thus balanced treatment groups
were achieved. All subjects in the trial were of white origin. Two sub-
jects in the placebo group dropped out voluntarily after 1 wk
because they were not able to maintain the strict VLED regime.
However, after exclusion of the data for these 2 subjects, the 2
groups still did not differ significantly in baseline characteristics
(data not shown). The most common adverse events related to treat-
ment were injection-site ecchymosis, pruritis, and pain. These occurred
with similar frequency in the PEG-OB and placebo groups and gener-
ally occurred only with the first or second series of injections. No signi-
ficant differences between the groups in vital signs, standard chem-
istry or hematology measures, or urine analysis results were detected.
Weight loss, body composition, energy expenditure, and
appetite profile
By day 46, treatment and energy restriction had resulted in
an absolute weight loss of 14.6 ± 0.8 kg (14.9 ± 0.7%) in the
PEG-OB group and of 11.8 ± 0.9 kg (12.4 ± 1.1%) in the
placebo group (P = 0.027; Figure 1). There was a significant
difference in absolute weight loss between the PEG-OB and
placebo groups on days 25, 43, and 46 (during the treatment
period) and on days 50 and 57 (during the follow-up period)
(Figure 1). The percentage of weight loss on days 43 and 50
was significantly different between the 2 groups (P = 0.013 and
0.045, respectively). A tendency for a difference in percentage
of weight loss was observed on days 46 and 57 of the study
(P = 0.062 and 0.068, respectively). Absolute and percentage
changes in BMI were significantly different between the PEG-
OB and placebo groups on days 43, 46, and 50 and day 43,
respectively.
The loss of fat mass accounted for most of the loss of body
mass in both the PEG-OB group and the placebo group (74%
compared with 79%; NS). The resting metabolic rate signifi-
cantly decreased in both groups after 6 wk of the VLED and
treatment, as did the respiratory quotient. The mean absolute
changes in resting metabolic rate and respiratory quotient of all
22 subjects were 0.817 ± 0.096 MJ/d and 0.05 ± 0.01,
respectively. None of the changes in body composition and
energy expenditure were significantly different between the 2
groups (Table 2). In addition, comparison of the changes in
resting metabolic rate adjusted for FFM over the treatment
period did not show any significant differences between the
PEG-OB and placebo groups. Appetite, which was measured
before breakfast, significantly changed from baseline after
the VLED and treatment: appetite decreased from 40 ± 17 to
34 ± 16 mm on the visual analogue scale in the PEG-OB group
but increased from 38 ± 17 to 48 ± 16 mm in the placebo group
(P = 0.03).
Metabolic profile and pharmacokinetics
The weight reduction observed during treatment was accom-
panied by a significant decrease in glucose, cholesterol, and tria-
cylglycerol concentrations and by a significant increase in
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TABLE 2
Effect of 46 d of weekly treatment with 80 mg pegylated human recombinant leptin [polyethylene glycol–OB protein (PEG-OB)] or matching placebo and
of severe energy restriction (2.1 MJ/d) on body composition and energy expenditure1
Placebo (n = 10) PEG-OB (n = 12)
Day 1 Day 46 Day 1 Day 46
FFM (kg)2 67.3 ± 2.3 64.9 ± 2.7 69.3 ± 1.3 65.6 ± 1.2
FM (kg)3 29.3 ± 1.9 19.9 ± 1.7 28.2 ± 1.8 17.3 ± 1.8
%FM (%)3 30.1 ± 1.1 23.2 ± 1.2 28.8 ± 1.5 20.6 ± 1.9
RMR (MJ/d)3 8.62 ± 0.25 7.27 ± 0.30 8.71 ± 0.19 7.67 ± 0.25
RQ4 0.814 ± 0.012 0.769 ± 0.012 0.822 ± 0.013 0.770 ± 0.010
1 x– ± SEM. FFM, fat-free mass; FM, fat mass; %FM, percentage of fat mass; RMR, resting metabolic rate; RQ, respiratory quotient. There were no signi-
ficant differences for time-by-group interaction (two-factor repeated-measures ANOVA).
2–4 Significant main effect of time (repeated-measures ANOVA): 2 P < 0.01, 3 P < 0.001, 4 P < 0.05.
-hydroxybutyrate, free fatty acid, and free glycerol concentra-
tions in the PEG-OB and placebo groups (Table 3). The changes
in metabolites were not significantly different between the 2
groups throughout the study. There were no effects of PEG-OB
treatment on glycemic control, as evidenced by serum insulin
concentrations (Table 3), glucose profiles obtained during the
baseline and end-of-treatment oral-glucose-tolerance tests, and
the estimated insulin resistance (HOMA-R method) at different
time points (data not shown).
Food restriction for 6 wk by means of a VLED reduced circu-
lating leptin concentrations to 2.0 ± 0.2 ng/mL (72%) in the
placebo group (Table 3). After weekly subcutaneous dosing, sus-
tained serum concentrations of total leptin (endogenous leptin
plus PEG-OB), which were measured just before the next dose
on days 8 and 15 and ranged from 950 to 3700 ng/mL, were
observed. Peak total leptin concentrations on days 25 and 46,
which were measured 72 h after subcutaneous injection, ranged
from 2300 to 6050 ng/mL.
DISCUSSION
In the present study, we show for the first time that exogenous lep-
tin induces additional weight loss in humans under severely energy-
restricted conditions. Weight loss in both the PEG-OB– and placebo-
treated subjects was primarily due to fat loss, which is in line with the
results of previous animal studies (2–4). However, the fact that
changes in fat mass contrary to changes in body weight did not dif-
fer significantly between the 2 groups in the present study may be
explained by the small sample size. Conservation of FFM, which was
observed in rodents treated with leptin (3, 22), was not observed in
the present study, in which both treatment groups lost equal amounts
of FFM after 6 wk of severe energy restriction. The loss of FFM in
both groups was within the normal physiologic range of 25% of
total body weight loss.
Treatment of normal mice with leptin prevented the decrease in
energy expenditure that would normally occur with a reduction in
food intake (22). As reported before, we failed to reproduce similar
results with humans under different energy-deficit conditions and
PEG-OB doses (10). Also, a study of never-obese subjects on a
weight-maintenance regimen failed to show an effect of leptin admin-
istration on energy metabolism (12). In contrast, a recent study
reported reversal of the effects of sustained weight reduction on
energy expenditure by a low dose of exogenous leptin (23). A reduc-
tion in appetite before breakfast under negative energy-balance con-
ditions was present in the PEG-OB–treated group at the end of the
present study. This result is consistent with the results of several
studies in rodents and primates that also showed a decline in food
intake after leptin administration (2–4, 24). Furthermore, reduc-
tions in appetite were also observed in our first study with 20 mg
PEG-OB/wk, but the effect was too small to result in additional
weight loss (25). Because the decrease in energy expenditure was
not significantly different in the 2 groups, it is conceivable that the
additional weight loss caused by PEG-OB administration was
largely attributable to reductions in appetite that resulted in better
compliance with the dietary restriction. Thus, the results above sug-
gest that exogenous leptin may influence human energy balance
during starvation by reducing appetite.
No other metabolic effects of leptin and PEG-OB observed in
animal studies were detected in the present study (5). Most promi-
nent among these were effects on fasting plasma glucose and
insulin, oral glucose tolerance, and triacylglycerol. We failed to
observe an additional enhancement of the well-known effects of
weight loss on these variables by weekly PEG-OB treatment in the
presence of severe energy restriction. These findings suggest that
leptin may not be directly involved in the regulation of these sys-
tems in humans under the conditions of this experiment. However,
these variables were not elevated in the group of overweight and
mildly obese men enrolled in this trial. Because the weight loss
induced by the energy restriction and negative energy balance
decreased fasting plasma glucose and insulin, oral glucose toler-
ance, and triacylglycerol, these improvements may have masked
the effects of PEG-OB treatment on these variables.
The findings of the present study are consistent with the character-
istics of homozygous human patients with total leptin deficiency or
nonfunctional leptin receptors (26–28). These rare and very obese
individuals have been shown to have a normal body temperature and
normal resting energy expenditure but to be markedly hyperphagic.
Also, the few such patients studied up to now exhibit normal glucose
homeostasis, a normal cholesterol concentration, and only moderate
impairments in metabolites such as free fatty acids and triacylglycerol
despite their severe obesity. In addition, mice heterozygous for the ob
gene (29, 30) and persons who are genetically partially deficient in
leptin (31) appear to have an intermediate phenotype. When a young,
very obese girl with a mutated ob gene received daily subcutaneous
treatment with human recombinant leptin, she experienced a rapid and
progressive reduction in body weight. This weight loss was mainly
due to a reduction in food intake as a result of decreased appetite and
food-seeking behavior but not to changes in energy expenditure (32).
The hypothesis first proposed by Flier and coworkers (13,
14) suggests that the falling concentration of leptin during star-
vation and its effects may constitute part of the thrifty geno-
type, a set of genes postulated to promote survival during periods
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TABLE 3
Effect of 46 d of weekly treatment with 80 mg pegylated human
recombinant leptin [polyethylene glycol–OB protein (PEG-OB)] or
matching placebo and of severe energy restriction (2.1 MJ/d) on
metabolites and endocrine measures1
Placebo (n = 10) PEG-OB (n = 12)
Glucose (mmol/L)2
Day 1 5.2 ± 0.07 5.3 ± 0.08
Day 8 4.7 ± 0.11 4.5 ± 0.10
Day 15 4.7 ± 0.16 4.6 ± 0.09
Day 25 4.6 ± 0.13 4.5 ± 0.11
Day 46 4.7 ± 0.16 4.7 ± 0.09
Cholesterol (mmol/L)2
Day 1 4.8 ± 0.27 4.7 ± 0.24
Day 8 4.7 ± 0.31 4.1 ± 0.25
Day 15 4.0 ± 0.21 3.4 ± 0.22
Day 25 3.3 ± 0.19 2.9 ± 0.16
Day 46 3.7 ± 0.17 3.2 ± 0.13
-Hydroxybutyrate (mol/L)2
Day 1 67 ± 10 80 ± 7
Day 8 848 ± 212 1146 ± 138
Day 15 987 ± 282 1131 ± 177
Day 25 1303 ± 402 1401 ± 252
Day 46 794 ± 199 806 ± 186
Triacylglycerol (mmol/L)3
Day 1 1.15 ± 0.19 1.13 ± 0.26
Day 8 0.69 ± 0.09 0.59 ± 0.06
Day 15 0.77 ± 0.10 0.67 ± 0.10
Day 25 0.83 ± 0.17 0.58 ± 0.06
Day 46 0.58 ± 0.07 0.48 ± 0.06
FFA (mol/L)3
Day 1 408 ± 48 382 ± 31
Day 8 704 ± 131 825 ± 67
Day 15 592 ± 73 664 ± 85
Day 25 553 ± 46 638 ± 34
Day 46 600 ± 50 597 ± 44
Free glycerol (mol/L)2
Day 1 63.3 ± 3.2 67.3 ± 2.6
Day 8 134.8 ± 16.9 137.9 ± 14.0
Day 15 125.0 ± 11.5 132.7 ± 13.9
Day 25 85.0 ± 4.0 83.1 ± 4.9
Day 46 67.7 ± 4.4 77.8 ± 4.9
Insulin (mU/L)2
Day 1 9.4 ± 1.0 7.2 ± 0.8
Day 8 4.5 ± 0.7 3.4 ± 0.6
Day 15 5.0 ± 1.1 3.2 ± 0.5
Day 25 3.4 ± 0.6 2.2 ± 0.4
Day 46 3.6 ± 0.7 2.0 ± 0.3
Total leptin (ng/mL)4
Day 1 7.1 ± 0.8 7.6 ± 1.2
Day 8 3.4 ± 0.6 1828 ± 183
Day 15 3.1 ± 0.5 2777 ± 194
Day 25 2.1 ± 0.3 4194 ± 285
Day 46 2.0 ± 0.2 3980 ± 203
1 x– ± SEM. FFA, free fatty acids. There were no significant differences
for time-by-group interaction (two-factor repeated-measures ANOVA),
except for total leptin (P < 0.001).
2,3 Significant main effect of time (repeated-measures ANOVA): 2 P <
0.01, 3 P < 0.05.
4 The assay did not distinguish between endogenous leptin and PEG-OB.
of insufficient energy intake in human evolution by increasing
the efficiency of energy storage. In this updated thrifty geno-
type concept, the decrease in leptin concentrations during peri-
ods of limited energy intake might signal the brain to initiate
several physiologic responses to increase the chances of sur-
vival. In addition, this concept suggests that an effective adi-
postatic role of leptin would subvert the thrifty genotype by
limiting the capacity of energy storage during periods of
abundance, which would result in reduced survival in subse-
quent periods of food shortages. Stated differently, evolution
would favor resistance to leptin action when leptin concen-
trations are rising or high during periods of sufficient energy
intake or storage. The fact that exogenous leptin resulted in
additional weight loss only during severe energy restriction
in the present study but failed to significantly affect weight
loss during mild hypoenergetic conditions in the previous
study (11) with comparable total leptin concentrations
appears to support this concept.
Whether the results of the present study can be generalized to
subjects with a BMI > 32 is uncertain. However, evidence show-
ing that the marked decrease in leptin production and leptin con-
centrations after fasting is reduced in obesity suggests that fast-
ing-induced adaptations to starvation and the effect of exogenous
leptin may depend on the degree of obesity present (33).
In summary, our results support the hypothesis that the physi-
ologic role of leptin is as a signal of starvation. We propose that
falling concentrations of leptin after severe energy restriction
influence human energy regulation by increasing appetite.
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